We invest in early-stage private companies with potential to go public, primarily in North American markets. Our portfolio companies range from producers of psychedelic compounds (both natural and synthetic), to clinical trial sponsors and companies developing innovative products in the space. We take an active role in helping our portfolio companies navigate the capital markets in North America. Our team has extensive experience in taking companies public in North America, on the NASDAQ, TSX and other Canadian exchanges